跳到主要內容

10X Fund, L.P. 的 Form 4/A 修正申報

修正

Galectin Therapeutics Inc(GALT),2022/8/15 申報

申報編號
0001493152-22-022804
申報時間
2022/8/15
交易日
2022/7/27
申報延遲
19 天
10b5-1 計畫
表單沒有這欄(2023 年以前)
原始申報日
2022/8/9

這份申報列了 1 筆非衍生性交易。公開市場賣出合計 $2.09 萬。交易後 19 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
10X Fund, L.P.CIK 0001453356持股 10% 以上大股東

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2022/7/27Common StockS賣出處分−10,000$2.09−$20,9006,168,940直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F1

Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan.

F2

10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

看 SEC EDGAR 上的完整原文 (在新分頁開啟)